A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Completed · Phase 2 · NCT05563246
Conditions: Lipoprotein Disorder
At a glance
- Research payments reported, 2025
- $6,630
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 233
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3473329 (drug), Placebo (drug)
- Dates
- Started 2022-11-24; completion 2024-03-14
- Results posted
- Yes
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
From ClinicalTrials.gov, last updated 2025-03-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $6,630 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Care Access Research LLC $3,930
- Cleveland Clinic, OH $2,700
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.